Search results for "Response rate"

showing 10 items of 122 documents

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

2016

<b><i>Purpose:</i></b> The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. <b><i>Methods:</i></b> Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m<sup>2</sup> every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The…

OncologyMalemedicine.medical_specialtyCancer Research030232 urology & nephrologyProstate neoplasmAntineoplastic AgentsDocetaxelCastration resistantAdenocarcinomaTaxaneSingle CenterAntineoplastic Agent03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineTaxoidmedicineClinical endpointHumansProspective StudiesAgedResponse rate (survey)GynecologyCabazitaxelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMetastatic castration-resistant prostate cancerProspective StudieProstatic Neoplasms Castration-ResistantDocetaxelOncologyCabazitaxel030220 oncology & carcinogenesisChemotherapy regimenDisease ProgressionPrednisoneTaxoidsbusinessmedicine.drugHuman
researchProduct

Immunotherapeutic Advances for NSCLC.

2021

Abstract Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally advanced as well as in early-stage NSCLC. Assessment of tumor PD-L1 expression by immunohistochemistry has entered into routine clinical practice to select patients for immunotherapy, even though its predictive role has long been debated. Despite improved survival outcomes over standard chemotherapy, treatment with ICIs is associated with i…

OncologyResponse rate (survey)medicine.medical_specialtyTumor microenvironmentChemotherapybusiness.industryImmune checkpoint inhibitorsmedicine.medical_treatmentGastroenterologyImproved survivalDiseaseImmunotherapyReviewanti-PD-1/PD-L1 antibodiesOncologyRheumatologyInternal medicineImmunology and AllergyMedicinePharmacology (medical)immunotherapybusinessnon-small cell lung cancerPredictive biomarkerBiologics : targetstherapy
researchProduct

455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in …

2021

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryConcordanceFirst lineHematologymedicine.diseaseOverall response rateOncologyCell-free fetal DNAInternal medicineCohortmedicineMutational statusbusinessAnnals of Oncology
researchProduct

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

2015

Abstract: Background: Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods: Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (ly-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities. Results: Six eligible trials (741 patients) were selected. Pooled analysis showed a significan…

Oncologymedicine.medical_specialtyLung NeoplasmsPhase iii trialsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationSettore MED/21 - Chirurgia ToracicaNSCLClaw.inventionSingle agentOverall response rateRandomized controlled trialPerformance statuNSCLC; Chemotherapy; Performance status; Platinum; Doublet; Single agentlawCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIntensive care medicineeducationRandomized Controlled Trials as TopicPlatinumChemotherapyeducation.field_of_studyPerformance statusbusiness.industryHematologySurvival RateOncologyMeta-analysisDoubletNon small cellHuman medicinePerformance statusbusiness
researchProduct

Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

2008

A growing percentage of patients affected by advanced non-small cell lung cancer who progressed after first-line chemotherapy still have a good performance status and require second-line treatment.An overview of the state of the art of second-line therapeutic options is presented.The scope of the review is to give an update on the therapeutic options currently available for the second-line treatment of patients with advanced non-small cell lung cancer.Among chemotherapeutic drugs docetaxel and pemetrexed have been approved for second-line treatment of advanced non-small cell lung cancer. Although the drugs are equiactive in terms of response rate and survival parameters the latter has a cle…

Oncologymedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansPharmacology (medical)Lung cancerSalvage TherapyPharmacologyResponse rate (survey)Clinical Trials as TopicChemotherapyPerformance statusbusiness.industryDecision TreesGeneral Medicinemedicine.diseaseTreatment OutcomePemetrexedDocetaxelTolerabilityQuality of LifeErlotinibbusinessmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Evaluation of the effectiveness of drug prevention programs: Analysis of the international scientific production (2002–2011)

2015

s / Drug and Alcohol Dependence 146 (2015) e202–e284 e205 Oxytocin effects on human aggressive responding Joseph L. Alcorn, Nadeeka Dias, N. Rathnayaka, Joy Schmitz, C. Green, Scott D. Lane Department of Psychiatry & Behavioral Sciences, School of Medicine, Program in Neuroscience, Graduate School of Biomedical Sciences, University of Texas Health Science Center – Houston, Houston, TX, United States Aims: In the search for interventions aimed at improving the social functioning of individuals with substance use disorders (SUD), the neuropeptide oxytocin (OT) and the oxytonergic system may hold promise as an intervention strategy for promoting prosocial behaviors. Acute administration of OT …

PharmacologyResponse rate (survey)medicine.medical_specialtyAggressionPsychological interventionScopusBehavioural sciencesToxicologymedicine.diseaselanguage.human_languageSubstance abusePsychiatry and Mental healthProsocial behaviormedicinelanguagePharmacology (medical)medicine.symptomPortuguesePsychiatryPsychologyDrug and Alcohol Dependence
researchProduct

Public Health Genomics education in post-graduate schools of hygiene and preventive medicine: a cross-sectional survey.

2014

Background The relevance of Public Health Genomics (PHG) education among public health specialists has been recently acknowledged by the Association of Schools of Public Health in the European Region. The aim of this cross-sectional survey was to assess the prevalence of post-graduate public health schools for medical doctors which offer PHG training in Italy. Methods The directors of the 33 Italian public health schools were interviewed for the presence of a PHG course in place. We stratified by geographical area (North, Centre and South) of the schools. We performed comparisons of categorical data using the chi-squared test. Results The response rate was 73% (24/33 schools). Among respond…

Post-graduate medical education; Public Health Genomicsmedicine.medical_specialtymedia_common.quotation_subjectPost-graduate medical educationeducationSettore MED/42 - Igiene Generale E ApplicataEducationHygienemedicineHumansSurveyCurriculumPublic Health Genomicsmedia_commonPreventive healthcareGeographic differenceMedicine(all)Response rate (survey)Public health genomicsMedical educationPublic healthbusiness.industryPublic healthHygieneGeneral MedicineGenomicsTest (assessment)Cross-Sectional StudiesItalyEducation Medical GraduateFamily medicineEducation Public Health ProfessionalCurriculumPreventive MedicinebusinessResearch Article
researchProduct

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELI…

2013

8507 Background: Therapies approved in US for R/R PTCL have overall response rates (ORR) of 25%-27%. The need for new therapies persists. BELIEF is a pivotal, single-arm study of belinostat in patients with R/R PTCL after failure of ≥1 prior systemic therapies. Methods: Entry criteria were measurable PTCL, platelets ≥ 50,000/µL, no prior HDACi therapy, and adequate organ function. PTCL was confirmed by central pathology review (CPRG). Belinostat 30 min IV infusion at 1000 mg/m2was administered on days 1–5 of a 3 week cycle until progression or unacceptable toxicity. Tumor response was assessed by Cheson 2007 criteria. The primary endpoint was ORR. Results: Patients with R/R PTCL (N=129, 53…

Refractory Peripheral T-cell LymphomaCancer Researchmedicine.drug_classbusiness.industryHistone deacetylase inhibitorchemistry.chemical_compoundOverall response rateOncologychemistryImmunologymedicineCancer researchbusinessBelinostatJournal of Clinical Oncology
researchProduct

Patient engagement with research:European population register study

2014

Background Lay involvement in implementation of research evidence into practice may include using research findings to guide individual care, as well as involvement in research processes and policy development. Little is known about the conditions required for such involvement. Aim To assess stroke survivors’ research awareness, use of research evidence in their own care and readiness to be involved in research processes. Methods Cross sectional survey of stroke survivors participating in population-based stroke registers in six European centres. Results The response rate was 74% (481/647). Reasons for participation in register research included responding to clinician request (56%) and to …

Register (sociolinguistics)Malemedicine.medical_specialtyBiomedical ResearchCross-sectional studyPopulationPatient engagementNursingmedicineHumansRegistriesSurvivorseducationStrokeRegister studyAgedResponse rate (survey)Aged 80 and overeducation.field_of_studybusiness.industryPublic Health Environmental and Occupational HealthEuropean populationMiddle Agedmedicine.diseaseEuropeStrokeCross-Sectional StudiesFamily medicineFemalePatient ParticipationbusinessAttitude to HealthOriginal Research Papers
researchProduct

Selection bias was reduced by recontacting nonparticipants

2016

Objective One of the main goals of health examination surveys is to provide unbiased estimates of health indicators at the population level. We demonstrate how multiple imputation methods may help to reduce the selection bias if partial data on some nonparticipants are collected. Study Design and Setting In the FINRISK 2007 study, a population-based health study conducted in Finland, a random sample of 10,000 men and women aged 25–74 years were invited to participate. The study included a questionnaire data collection and a health examination. A total of 6,255 individuals participated in the study. Out of 3,745 nonparticipants, 473 returned a simplified questionnaire after a recontact. Both…

Research designAdultMaleBiomedical Researchbiasmultiple imputationEpidemiologyCross-sectional studymedia_common.quotation_subjectPopulation01 natural sciencesProxy (climate)010104 statistics & probability03 medical and health sciencesmissing data0302 clinical medicinenon-responseStatisticsHumanssurvey030212 general & internal medicine0101 mathematicseducationFinlandSelection Biasmedia_commonAgedResponse rate (survey)Selection biasAged 80 and overeducation.field_of_studyta112Patient Selectionta3142Middle AgedMissing dataHealth indicatorCross-Sectional StudiesResearch DesignFemalePsychologyDemographyFollow-Up Studies
researchProduct